5244042026-04-012026-06-305244042026-04-012026-06-30in-capmkt:OtherExpenses1Member5244042026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15244042026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524404MARKSANSNOTLISTEDINE750C01026Marksans Pharma LimitedMain BoardEquity2026-04-012027-03-312026-08-122026-07-31INRMillionsQuarterlyFirst quarterSingle segmentPharmaceutical Formulation2026-08-1210:50:002026-08-1212:10:00Declaration of unmodified opinion2026-04-012026-06-30UnauditedConsolidated8407960000254040000866200000022066900001384490000-15652000011429400007004000024864000017000100006596290000206571000002065710000518840000-472000004716400000159407000000001594070000170240000176431000015716700002240000017385700002574000045316000013.473.47003.473.471. The consolidated unaudited financial results of the Company for the quarter ended 30 June 2026 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12 August 2026. The Statutory Auditors of the Company have carried out a limited review of the above results in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 ('the Regulations'), as amended and expressed an unmodified conclusion. <br /> <br /> 2. The consolidated unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid dwn in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulations. <br /> <br /> 3. The figures for the quarter ended 31 March 2026 represents the derived figures between the audited figures in respect of full financial year ended 31 Mach 2026 and the unaudited published year-to-date figures up to 31 December 2025, being the date of the end of the third quarter of the financial year which were subjected to limited review by the statutory auditor of the Company. <br /> <br /> 4. The Group has a single business segment 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments. <br /> <br /> 5. Other income net includes net gain on foreign exchange differences amounting to Rs. 120.01 millions for the quarter ended 30 June 2026 (31 March 2026: net gain of Rs. 247.99 millions, 30 June 2025: net loss of Rs. 38.93 millions, year ended 31 March 2026: net gain of Rs. 500.95 millions). <br /> <br /> 6. During the current quarter, the Company has acquired 100% share capital of QliniQ B.V., a company based in Netherlands, for a consideration of EUR 7.50 Million. QliniQ B.V. specializes in bringing innovative healthcare solutions to the Dutch market through the marketing and distribution of prescription medicines and mdical devices. QliniQ B.V. is a subsidiary of the company w.e.f. 1 April 2026. As per Ind AS 103 on ‘Business Combinations’, purchase consideration has been allocated on a provisional basis, pending final determination of the fair value of the acquired assets and liabilities. <br /> <br /> 7. Subsequent to the quarter ended 30 June 2026, the Company entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany-based pharmaceutical company with frontend sales, marketing, and distribution capabilities across German healthcare market, for a cash consideration of EUR 1.10 Million. The acquisition was subsequently completed, following which ABCnow GmbH became a wholly owned subsidiary of the Company. <br /> <br /> 8.During the quarter ended 30 June 2026, the company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees of the Company and its subsidiay companies. Each stock option is exercisable into one equity share of the Company having a face value of Rs.1 each. Other Expenses1700010000Remeasurements of the net defined benefit Plans34800003480000880000Foreign currency translation reserve (net)1676400001676400000170240000UnauditedtrueM S K A & Associatestrue2027-07-31